Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:39:54 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



Q:RYTM - RHYTHM PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RYTM - Q0.138.33·44.001.543.76+2.786.8920.839,5617,49342.49  44.00  41.8652.57  15.500117:30:08Apr 2915 min RT 2¢

Recent Trades - Last 10 of 7493
Time ETExPriceChangeVolume
17:30:08Q42.141.161
16:53:19Q42.491.511
16:42:08Q42.19541.21541
16:21:19Q43.762.7815
16:20:00Q43.762.78244
16:00:06Q43.762.78346
16:00:06Q43.762.78849
16:00:06Q43.762.78300
16:00:06Q43.762.78107,300
16:00:06Q43.762.7836

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-29 18:30U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
2024-04-24 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
2024-04-16 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2024-04-01 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
2024-03-25 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
2024-03-11 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2024-03-06 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
2024-02-22 07:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
2024-02-22 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results ‚  and Business Update
2024-02-08 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2024-02-07 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE ‚ ® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
2024-01-31 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
2024-01-12 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2024-01-04 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
2024-01-04 06:58U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
2023-12-15 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2023-12-13 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
2023-12-06 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
2023-11-13 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Employment Inducement Grants
2023-11-07 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results ‚  and Business Update